Achieving sustained virological response (SVR; cure) in hepatitis C patients using a simple regimen is key to making elimination by 2030 possible. In the largest real‐world analysis to date, the effectiveness of pangenotypic, panfibrotic, single‐tablet, sofosbuvir/velpatasvir (SOF/VEL) once‐daily for 12 weeks was assessed in 12 clinical real‐world cohorts from various geographical areas, settings and treatment practices. Factors affecting risk of not achieving SVR were assessed.

中文翻译：

---

Sofosbuvir / velpatasvir作为简单有效的HCV治疗的全球真实证据：分析了12个队列的5552名患者。

使用简单的方案在丙型肝炎患者中实现持续的病毒学应答（SVR；治愈）是在2030年之前消除病毒的关键。在迄今为止最大的现实世界分析中，在来自不同地区，环境的12个临床现实队列中，每天一次评估泛基因型，泛纤维化，单片，sofosbuvir / velpatasvir（SOF / VEL）的有效性，持续12周和治疗方法。评估影响未达到SVR风险的因素。